Cumberland patents expiration
1. Sancuso patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608282 | CUMBERLAND | Transdermal granisetron |
Jan, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NE(NE) | Sep 12, 2011 |
| New Dosage Form(NDF) | Sep 12, 2011 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
SANCUSO family patents
2. Vaprisol patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) | |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with euvolemic hyponatremia
Dosage: INJECTABLE;INTRAVENOUS
VAPRISOL family patents
3. Vaprisol In 5% Dextrose In Plastic Container patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5723606 | CUMBERLAND | Condensed benzazepine derivative and pharmaceutical composition thereof |
Dec, 2019
(4 years ago) | |
Drugs and Companies using CONIVAPTAN HYDROCHLORIDE ingredient
Market Authorisation Date: 29 December, 2005
Treatment: Method of using antagonist of arginine vasopressin (ava) v1a and v2 receptors for intravenous treatment of patients with euvolemic hyponatremia
Dosage: INJECTABLE;INTRAVENOUS
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER family patents
4. Vibativ patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351691 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US7208471 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US6635618 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Sep, 2023
(7 months ago) | |
| US7531623 | CUMBERLAND | Hydrochloride salts of a glycopeptide phosphonate derivative |
Jan, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7700550 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US8101575 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US7544364 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
| US8158580 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May, 2021
(2 years ago) | |
| US7008923 | CUMBERLAND | Glycopeptide phosphonate derivatives |
May, 2021
(2 years ago) | |
| US6872701 | CUMBERLAND | Glycopeptide phosphonate derivatives |
Jun, 2021
(2 years ago) | |
| US6858584 | CUMBERLAND | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug, 2022
(1 year, 8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-673) | Jun 21, 2016 |
| New Chemical Entity Exclusivity(NCE) | Sep 11, 2014 |
Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 11 September, 2013
Market Authorisation Date: 11 September, 2009
Treatment: Method of treating bacterial infections; Method of treating a staphylococcal infection; Method for treating bacterial infection
Dosage: POWDER;INTRAVENOUS
VIBATIV family patents